liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Patterns of use and outcomes of peripherally inserted central catheters in hospitalized patients with solid tumors: A multicenter study
Univ Michigan Hlth Syst, MI USA.
Univ Michigan Hlth Syst, MI USA.
Linköping University, Department of Biomedical and Clinical Sciences, Division of Clinical Chemistry and Pharmacology. Linköping University, Faculty of Medicine and Health Sciences. Ryhov Cty Hosp, Sweden.ORCID iD: 0000-0001-8711-9044
Univ Michigan Hlth Syst, MI USA.
Show others and affiliations
2022 (English)In: Cancer, ISSN 0008-543X, E-ISSN 1097-0142, Vol. 128, no 20, p. 3681-3690Article in journal (Refereed) Published
Abstract [en]

Background The risk of peripherally inserted central catheter (PICC)-related complications in patients hospitalized with solid tumors remains unclear. Existing studies are limited by single-center, outpatient designs and include heterogenous patients. Methods A retrospective cohort study was designed and included adult patients with solid organ cancers who were admitted to a general medicine ward or intensive care unit and received a PICC. Data were collected from November 2013 to December 2019 at 50 Michigan hospitals. Major complications were defined as central line-associated bloodstream infection, deep vein thrombosis, pulmonary embolism, and catheter occlusion. Hospital variation in PICC use and outcomes was examined. Results Data included 3235 hospitalized patients with solid tumors who had PICCs placed for 51,047 catheter days. Most catheters were double-lumen devices (57.0%). Notably, 17.5% of patients had another central venous catheter at the time of PICC insertion. The most common indications for PICC use were antibiotics (34.5%) and difficult access or blood draws (21.6%); chemotherapy was the primary indication in only 15.7% of patients. A major PICC-related complication occurred in 491 patients (15.2%); catheter occlusion was the most prevalent complication (n = 322; 10.0%) followed by deep vein thrombosis (n = 116; 3.6%), central line-associated bloodstream infection (n = 82; 2.5%), and pulmonary embolism (n = 20; 0.6%). Significant variation in indications for PICC use, device characteristics, and frequency of major complications across hospitals was observed (p < .001). Conclusions PICCs were associated with significant complications in hospitalized patients who had solid malignancies and were often used for reasons other than chemotherapy. Policies and guidance for the appropriate use of PICCs in oncologic patients appear necessary. Lay summary Peripherally inserted central catheters (PICCs) are devices placed in peripheral veins to deliver medication to large veins near the heart. PICCs are used frequently in oncology. The objective of this report was to describe PICC-associated complications in hospitalized patients with solid tumors. This study was performed across 50 Michigan hospitals and included 3235 patients with solid tumor cancers and who had a PICC. Overall, 15.2% of patients experienced a complication, including central line-associated bloodstream infections, deep vein thrombosis, pulmonary embolism, or catheter occlusion. Complication rates varied across hospitals. PICCs are associated with substantial complications in hospitalized patients with solid tumors.

Place, publisher, year, edition, pages
WILEY , 2022. Vol. 128, no 20, p. 3681-3690
Keywords [en]
central venous catheters; neoplasms; neoplasms; oncology; peripherally inserted central catheters; quality improvement; retrospective studies; venous thrombosis
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-187720DOI: 10.1002/cncr.34410ISI: 000837739100001PubMedID: 35943390OAI: oai:DiVA.org:liu-187720DiVA, id: diva2:1691208
Note

Funding Agencies|Blue Cross and Blue Shield of Michigan (BCBSM); Blue Care Network as part of the BCBSM Value Partnerships Program

Available from: 2022-08-29 Created: 2022-08-29 Last updated: 2025-02-18Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Taxbro, Knut

Search in DiVA

By author/editor
Taxbro, Knut
By organisation
Division of Clinical Chemistry and PharmacologyFaculty of Medicine and Health Sciences
In the same journal
Cancer
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 115 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf